Scholars Central

EditorialPublished 22 Jul 2011

Human Papillomavirus (HPV) Vaccine: Is it worthwhile?

Authors: Marlene F Shehata, Alan Pater

Journal of Biotechnology & Biomaterials

Volume 1 · Issue 4 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Cervical cancer is one of the most common cancers in women. Human Papillomavirus (HPV) is the primary cause of cervical, anal, vulvar, vaginal and penile cancers as well as genital warts. Over 120 types of HPV have been isolated with more than 40 of these types infecting the epithelial lining of the anal and genital tracts [6]. HPV infections can be currently screened using the Pap cytology and the HPV DNA testing [7]. False positive Pap tests can greatly impact the patient’s psychological status and is currently costing over $ 244 M/year [10]. Given the huge economic burden associated with Pap cytology and DNA testing, the purpose of this editorial is to discuss the value of HPV vaccines in preventing HPV infections and hence reducing the economic burden of HPV diagnostic testing.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Biotechnology & Biomaterials.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Biotechnology & Biomaterials
  • SubjectBiochemistry & Biotechnology
  • SubjectMaterials Science
  • BylineArticles whose byline prints “Marlene F Shehata”
  • BylineArticles whose byline prints “Alan Pater”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels